ox-LDL plus 5 mol/L PDTC; 10, 80 g/ml ox-LDL plus 10 mol/L PDTC; 11, 80 g/ml ox-LDL plus 15 mol/L PDTC. The groups of ox-LDL plus PDTC or atorvastatin were pretreated with PDTC or atorvastatin for 6 h before adding ox-LDL.
Preparation and Ox-LDL
Human LDL was isolated through sequential ultracentrifugation and oxidated, as described elsewhere. Antioxidantfree LDL (0.3 mg protein/ml) was incubated with CuSO4 (5 mol/L) for 24 h at 23°C. The degree of LDL oxidation was estimated by measuring the amounts of thiobarbituric acid-reactive substances (TBARS) produced using a colorimetric assay for malondialdehyde (MDA). Native LDL had the TBARS value of 7.5±2.1 nmol/mg, and LDL samples that had been oxidized by exposure to CuSO4 exhibited higher levels of oxidative modification, with TBARS values of 13.0±1.4 nmol/mg. [12] [13] 
Measurement of MDA, Activities of Total Superoxide Dismutase (SOD) and BMP-2 Protein Production in HUVECs
Levels of MDA in cultured cells were measured as TBARS, as described elsewhere. [14] [15] TBARS were extracted in a mixture of butanol and pyridine, which was separated by centrifugation. Activities of total SOD were measured photometrically according to standard protocols. [16] [17] BMP-2 in culture media was quantified using an enzyme-linked immunosorbent assay, according to the manufacturer's recommendations. The monoclonal anti-human BMP-2 antibody (from R&D Systems Inc, Minneapolis, MN, USA) was used in the present study. According to the manufacturer, there is no known cross-reactivity with other known cytokines in this assay. The sensitivity for BMP-2 was 29 pg/ml. The absorption of each well was measured at 450 nm, using a microplate spectrophotometer. Each sample was assayed in duplicate. Intra-assay and inter-assay precision variability was <8%.
Real-Time PCR
Total RNA from HUVECs was extracted according to the RNeasy protocol (Qiagen, Hilden, Germany). One microgram of total RNA underwent reverse transcription into cDNA in a volume of 20 l of avian myeloma leukemia virus reverse transcriptase and oligo dT primers (Promega, Madison, WI, USA), according to the manufacturer's manual. Real-time PCR measurement of BMP-2 cDNA was performed with the light cycler instrument (Roche), using the Fast Start DNA Master SYBR Green I kit (Roche Diagnostics, Mannheim, Germany). For verification of the correct amplification product, PCRs were analyzed on a 2% agarose gel stained with ethidium bromide. The specific primer pair for BMP-2 resulting in a 189-bp PCR product was: sense primer 5'-GGTGGAATGACTGGATTG-3', reverse primer 5'-GCATCGAGATAGCACTG-3'. Each reaction (20 l) contained 2 l cDNA, 2.5 mmol/L MgCl2, 1 pmol of each primer and 2 l of Fast Starter Mix (containing buffer, dNTPs, Sybr Green dye and Taq polymerase). The amplification program consisted of one cycle at 95 C with a 30-s hold followed by 39 cycles at 95 C with a 5-s hold, at 65 C annealing temperature with a 10-s hold and at 72 C with a 20-s hold. After amplification, melting curve analysis was done to verify the correctness of the amplicon. A negative control without cDNA was run with every PCR to assess the specificity of the reaction. Analysis of data was performed using Light Cycler software version 3.5. PCR efficiency was determined by analyzing a dilution series of cDNA (external standard curve). The identity of the PCR product was confirmed by comparing its melting temperature (Tm) with the Tm of amplicons from standards or positive controls. The -actin was analyzed in parallel with each PCR and the resulting -actin values were used as standards for presentation of BMP-2 transcripts.
RNA Isolation and RT-PCR
All glassware was treated with DEPC to inhibit RNases. Total RNA was extracted from HUVECs, respectively, using Trizol reagent, following the manufacturer's instructions. RNA underwent reverse transcription, and the resulting cDNA obtained was used for PCR amplification to estimate the expression of BMP-2. The -actin was used as the endogenous control gene for normalization. The primer sequences used were: (1) BMP-2 forward primer 5'-GGTG-GAATGACTGGATTG-3', reverse primer 5'-GCATCGA-GATAGCACTG-3', yielding a 189-bp size product; and (2) -actin forward primer 5'-GATAGCATTGCTTTCGTGT-3', reverse primer 5'-TTCAACTGGTCTCAAGTCAG-3', yielding a 215-bp size product.
The PCR thermocycling conditions for the genes were as follows: an initial denaturation for 4 min at 94°C, 36 cycles with denaturation at 94°C for 60 s, primer annealing at 58°C (BMP-2) and 60°C ( -actin) for 60 s, and primer extension at 72°C for 60 s, and a final extension step at 72°C for 12 min. Each PCR product (5 l) was subjected to 1.5% agarose gel electrophoresis containing ethidium bromide, and was scanned by Bio-Rad Gel Doc 2000 Imaging System and analyzed for optical density through Quantity One 4.03 analysis software. The results for BMP-2 mRNA levels were presented relative to the expression of -actin.
Western Blot Analysis
The cells in dishes were washed 3 times in phosphate-buffered saline (PBS), lysed in 250 l of lysis buffer (50mmol/L Tris-HCl, pH 8.0; 150mmol/L NaCl, 0.02% sodium vandate, 0.1% SDS, 0.5% deoxycholic acid, 100 g/ml PMSF (phenylmethyl sulfonylfluoride), 0.2 g/ml leupeptin, 1% NP-40). Samples were separated on 12% SDS-PAGE (sodium dodecyl sulphate -polyacrylamide gel electropheresis) gel, and transferred onto PVDF (polyvinylidene difluoride) filters by a wet transferring system. The membrane was blocked with Blotto-Tween (5% non-fat milk and 0.05% Tween 20 in PBS) and incubated with the primary antibodies against NF-B p65 and -actin for 2 h at room temperature. After that, horseradish peroxidase-conjugated secondary IgG was added for 1 h at room temperature. The blots were developed according to the enhanced chemiluminescence protocol (Zhongshan Biotechnology, Beijing, China).
Effect of Agents on Cytoplasmic and Nuclear Levels of NF-B p65
The effect of agents on the activation of NF-B in HUVECs was determined using an assay kit from Active Motif (Carlsbad, CA, USA). This kit measures free p65, which is generated when NF-B is activated. To obtain assay material, the cells were seeded at 1.0×10 6 cells/25 cm 2 flask and were harvested after the treatment of these agents. Cytoplasmic and nuclear cell fractions were collected using the reagents supplied in the Nuclear Extract Kit (Active Motif). The cells were harvested by scraping and pelleted by centrifugation at 2,000×g at 4°C for 75 s. The pelleted cells were resuspended in 200 l of hypotonic buffer and incubated on ice for 15 min. Nonidet P-40 (Sigma Chemical Co, St Louis, MO, USA), a solubilizing agent, was added and the cells were vortexed for 10 s. The material was centrifuged for 45 s at 14,000×g at 4°C. The supernatant fluids (cytoplasmic fractions) were transferred to pre-chilled microcentrifuge tubes and stored at -80°C.
The nuclear pellets obtained above were resuspended in a lysis buffer supplied in the kit, and then vortexed for 10 s. This suspension was incubated for 30 min on ice on a rocking platform, vortexed for 30 s, and then centrifuged for 10 min at 14,000×g at 4°C. The supernatant fluids (nuclear fractions) were transferred to pre-chilled microcentrifuge tubes and stored at -80°C.
To assay the nuclear and cytoplasmic samples for amounts of p65, 20 l samples were added to wells of a 96-well plate that was coated with an oligonucleotide containing an NF-B consensus binding site. The p65 subunit of the activated NF-B contained in cell extracts specifically binds to this oligonucleotide. The plate was incubated for 1 h at room temperature on a rocking platform. After washing, an antibody to p65 was added and incubated for 1 h at room temperature. The wells were then washed, and an HRP-conjugated antibody was added and incubated for 1 h at room temperature. After washing, a substrate solution was added to the wells and incubated at room temperature for 10 min, protected from light. Stop solution (2N H2SO4) was added and the absorbance was read at 450 nm.
Amounts of protein in the fractions were determined by a modification of the method of Lowry et al 18 and Oyama and Eagle. 19 Results were expressed as Abs450 nm/mg protein, and expressed as % control (ie, amount made by cells exposed to control medium, set at 100%).
Statistical Analysis
All data were presented as the mean ± SD. Comparisons among groups were performed by one-way ANOVA analysis. Differences were considered significant at a value of p<0.05 for all tests.
Results

Concentration and Time-Dependent Effect of ox-LDL on BMP-2 mRNA Expression
The concentration-dependent effect of ox-LDL on BMP-2 mRNA expression is shown in Fig 1. As shown in Fig 1,  compared with the control or native-LDL group, BMP-2 mRNA production was minimal without ox-LDL stimulation; however, incubation with different concentrations of ox-LDL led to a significant increase. Maximal BMP-2 production was observed after incubation of HUVECs with 80 g/ml ox-LDL. Both PDTC and atorvastatin treatment downregulated BMP-2 mRNA expression induced by ox-LDL.
To investigate the time dependency of ox-LDL on the transcription of BMP-2, we used real-time PCR to assess mRNA levels in HUVECs treated with ox-LDL for different time periods. Under control conditions (ie, unstimulated cells), very low BMP-2 mRNA levels were found. Stimulation of HUVECs with 80 g/ml ox-LDL led to a time-dependent increase in BMP-2 mRNA that peaked 12 h after ox-LDL application and decreased afterwards. After 24 h, BMP-2 mRNA was higher than in the control cells (but this increase was not significant). These results indicate that ox-LDL induced BMP-2 mRNA in HUVECs in a time-dependent manner (Fig 2) .
Measurement of Activities of Total SOD, MDA and BMP-2 in Supernatant of Cell Culture
The level of BMP-2, MDA and activities of total SOD in the cell culture are shown in Figs 3 and 4 . Fig 3A shows the increase in BMP-2 level caused by treatment with ox-LDL, but PDTC or atorvastatin treatment caused a significant decrease in BMP-2 protein level. Figs 3B,C shows that stimulation of ox-LDL caused increased MDA levels and decreased activities of total SOD in cultured HUVECs; however, this tendency was reversed with PDTC or atorvastatin treatment. *p<0.05 vs control group; p<0.05 vs 80 g/ml ox-LDL +15 mol/L pyrrolidine dithiocarbamate (PDTC); # p<0.05 vs 80 g/ml ox-LDL + 10 mol/L atorvastatin; p<0.05 vs 80 g/ml native-LDL. Group 1, control; group 2, 40 g/ml native-LDL; group 3, 80 g/ml native-LDL; group 4, 40 g/ml ox-LDL; group 5, 80 g/ml ox-LDL; group 6, 80 g/ml ox-LDL +1 mol/L atorvastatin; group 7, 80 g/ml ox-LDL + 5 mol/L atorvastatin; group 8, 80 g/ml ox-LDL + 10 mol/L atorvastatin; group 9, 80 g/ml ox-LDL + 5 mol/L PDTC; group 10, 80 g/ml ox-LDL + 10 mol/L PDTC; group 11, 80 g/ml ox-LDL + 15 mol/L PDTC. p<0.05 vs 80 g/ml oxidized (ox)-low-density lipoprotein (LDL) +15 mol/L pyrrolidine dithiocarbamate (PDTC); # p< 0.05 vs 80 g/ml ox-LDL +10 mol/L atorvastatin; p<0.05 vs 80 g/ml native-LDL. Group 1, control; group 2, 40 g/ml native-LDL; group 3, 80 g/ml native-LDL; group 4, 40 g/ml ox-LDL; group 5, 80 g/ml ox-LDL; group 6, 80 g/ml ox-LDL +1 mol/L atorvastatin; group 7, 80 g/ml ox-LDL +5 mol/L atorvastatin; group 8, 80 g/ml ox-LDL +10 mol/L atorvastatin; group 9, 80 g/ml ox-LDL + 5 mol/L PDTC; group 10, 80 g/ml ox-LDL +10 mol/L PDTC; group 11, 80 g/ml ox-LDL +15 mol/L PDTC. MDA, which peaked 12 h after ox-LDL application and decreased afterwards; however, compared with levels of BMP-2 and MDA, the level of SOD showed the opposite tendency after treatment with 80 g/ml ox-LDL.
Effect of ox-LDL on Cytoplasmic and Nuclear Levels of NF-B p65
In the HUVECs, ox-LDL caused an increase in levels of nuclear p65, reaching a maximum of approximately sixfold after treatment with 80 g/ml ox-LDL; however, this activation was inhibited by treatment with PDTC or atorvastatin ( Table 1 ). In the cytoplasm of these cells, compared with the control group and native-LDL group, a fourfold increase in p65 was seen for the 80 g/ml ox-LDL group, but this was decreased by PDTC or atorvastatin treatment (Table 1) .
Nuclear p65 was also detected by western blotting to assess the translocation of NF-B. Levels of the p65 subunit increased in the nuclear fraction of HUVECs induced by ox-LDL treatment. Compared with the control cultures that were not treated with ox-LDL, atorvastatin or PDTC treatment reduced p65 translocation to the nucleus after ox-LDL treatment (Fig 5) .
Discussion
BMP-2, a transforming growth factor superfamily member, plays an important role both in vascular development and pathophysiological processes. Mice genetically engineered to be deficient in BMP-2 die between days 7 and 10 of gestation of cardiac defects before boneformation. 20 BMP-2 plays imortant roles in vascular calcification and atherosclerosis. 2, 3, 6, 7 Ox-LDL is considered a key trigger in the initiation and progression of atherosclerosis. 21 In atherosclerosis, ox-LDL accumulates in the vessel walls and causes endothelial dysfunction. [22] [23] Although many studies have demonstrated a clear association between ox-LDL accumulation and atherosclerotic calcification, little is known of the role of ox-LDL in regulating vascular calcification and the effect of atorvastatin on ox-LDL-induced BMP-2 expression. In the present study, we found ox-LDL can significantly increase BMP-2 expression, however, ox-LDL-induced BMP-2 expression was decreased by the treatment of atorvastatin. These findings suggest that ox-LDL-induced BMP-2 expression might have related with vascular calcification and the treatment of atorvastatin can inhibite the ox-LDL-induced BMP-2 expression.
Maziere et al demonstrated that ox-LDL induces activation of NF-B in endothelial cells and causes cell injury. 24 Activated NF-B has indeed been detected in endothelial cells of atherosclerotic plaques. 25 Collins suggested oxidative activation of endothelial cell transcription factors, especially NF-B, as a mechanism for changing endothelial cell phenotype and for initiating atherosclerotic lesions. 26 Hernan dez-Presa and colleagues provided direct evidence for NF-B activation in early atherosclerotic lesions. 27 In our study, we have shown that ox-LDL caused a significantly increase .05 vs 80 g/ml ox-LDL +10 mol/L atorvastatin; p< 0.05 vs 80 g/ml native-LDL. Group 1, control; group 2, 40 g/ml native-LDL; group 3, 80 g/ml native-LDL; group 4, 40 g/ml ox-LDL; group 5, 80 g/ml ox-LDL; group 6, 80 g/ml ox-LDL +1 mol/L atorvastatin; group 7, 80 g/ml ox-LDL + 5 mol/L atorvastatin; group 8, 80 g/ml ox-LDL +10 mol/L atorvastatin; group 9, 80 g/ml ox-LDL + 5 mol/L PDTC; group 10, 80 g/ml ox-LDL +10 mol/L PDTC; group 11, 80 g/ml ox-LDL +15 mol/L PDTC.
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in nuclear p65 levels, however, NF-B activation caused by ox-LDL can be inhibted by the treatment of atorvastatin or PDTC. These results indicate ox-LDL uptake BMP-2 expression potentially via NF-B activation. The present study is also to to evaluate the oxidative status in HUVECs by detecting the activity of antioxidant enzyme SOD together with the level of MDA, a well-known marker of oxidative stress. Measurements of MDA are potential candidates for general biomarkers of oxidative stress. It is well known that hypercholesterolemia is associated with increased levels of oxidative stress. The lipid peroxidation of cell membranes results in MDA formation, which possibly leads to tissue damage. [28] [29] In our present study, we observed that ox-LDL treatment can increase the MDA levels and decrease activities of total SOD, however, atorvastatin treatment significantly reduced MDA concentration and increase activities of total SOD, suggesting that atorvastatin had strong antioxidative property, which was supported by the previous study. 30 Protective effect of atorvastatin may partly be due to its ability to lower MDA concentration or increase antioxidant enzymes activity. These findinges also suggest that the excessive oxidative stress occurred during ox-LDL status and oxidative stress might take as a common mediator of such an effect of ox-LDL uptake BMP-2 expression.
Although some evidences have shown that statins itself enhance the expression of BMP-2, 31-32 in our research, atorvastatin can suppress ox-LDL-induced BMP-2 expression, which suggest that the powerful antioxidative stress effects of atorvastatin might supress the ox-LDL-induced BMP-2 mNRA expression by inhibiting NF-B expression. Therefore, our results suggest that atorvastatin may inhibit the ox-LDL-related BMP-2 expression in process of vascular calcification. Investigation of the BMP-2 expression induced by ox-LDL may provide a clue to understanding the pathophysiology of vascular calcification, and may lead to a new and promising therapeutic strategy.
